HS-10374 clinical trials
How each study uses HS-10374 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HS-10374 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Hansoh BioMedical R&D Company (5) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses HS-10374 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque PsoriasisNot yet recruitingPhase 2Hansoh BioMedical R&D CompanyNCT06926582Written as HS-10374 6mg tablets
- A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque PsoriasisNot yet recruitingPhase 3Hansoh BioMedical R&D CompanyNCT06672393Written as HS-10374 6mg tablets
- Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic ArthritisRecruitingPhase 2Hansoh BioMedical R&D CompanyNCT06176508Written as HS-10374
- A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque PsoriasisRecruitingPhase 2Hansoh BioMedical R&D CompanyNCT06077331Written as HS-10374 tablets 1mg
- A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®)CompletedPhase 1Hansoh BioMedical R&D CompanyNCT07181343Written as HS-10374 tablets
- A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy SubjectsCompletedPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06033742Written as HS-10374 tablets